Latest French reimbursement listings:
This article was originally published in Clinica
Executive Summary
The French health ministry has issued a series of decrees to confirm new reimbursement listings for several medical devices sold in the private healthcare sector. The listing has been expanded to include: a series of Taxus Liberte coronary stents, manufactured by Boston Scientific; a series of urogenital implants and accessories in the Ethicon TVT series of urogenital implants for sub-urethral support; Embogold micropheres, manufactured by Biopshere Medical, as arterial embolisation implants; and a series of Microval-Intra implants, for umbilical hernias and ruptures. The publication of these decrees is accompanied by price-volume agreements between the reimbursement authorities and the manufacturers for these products.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.